P3.03 Patient's Therapeutic Education and Breast Cancer : Impact of Pharmaceutical Interview on Quality of Life

Abstract

ABSTRACT Breast cancer is the most common women's malignant cancer in the world. Steps of diagnosis and initial treatment often lead to a deterioration of quality of life to patients who suffer of this cancer, especially treated by chemotherapy including taxoid.Our aim was to evaluate the impact of a pharmaceutical interview on improving their global quality of life. We have compared (from July 2011 to January 2012) the quality of life by a retrospective study between two randomized groups of patients with breast cancer (whatever the disease's stage), treated by taxoid, whose chemotherapy's initiation was performed at our institution. Quality of life was determined by the questionary QLQ-C30 of EORTC. 20 patients received a pharmaceutical interview during the first cure, and 28 not. The two groups are similar with regard to 10 studied items : age, neoadjuvant or adjuvant chemotherapy, TNM stage, SBR grade, hormone receptor status (estrogen and progesterone), HER2 status, and chemotherapy cycle's number. Both groups declare many side effects without difference concerning frequency of occurrence (95% vs. 96.4%; p = 1) and kind of side effect (nausea, constipation, diarrhea, oral mucositis[3DOTS]). The group with pharmaceutical interview has shown a significant improvement of global quality of life compared to the group without interview (respectively 70.4 vs. 54.8; p = 0.0046), especially on reducing fatigue (40 vs. 57.5; p = 0.0084), pain (19.2 vs. 36.3; p = 0.047), dyspnoea (20 vs. 34.6; p = 0.0494), and improving physical functionning (82.8 vs. 70.1; p = 0.0257) and cognitive functionning (83.3 vs. 67.3; p = 0.0326). An observation could be made about the methodology of our study. Indeed, the quality of life was not scored before the inclusion, so we can't know if the difference observed already existed. This study proves the importance of a pharmacist or a pharmaceutical team's involvement in the development and the participation to therapeutic education programs in medical oncology. These encouraging results deserve to be confirmed by a prospectively study with higher statistical power.